ArticleFrontiers in pharmacology2025
Mechanisms and safety evaluation of stir-fried atractylodis macrocephalae rhizoma with aurantii fructus in the treatment of inflammatory bowel disease: a study based on organ-on-a-chip model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FOXO: a key target in regulating aging and age-related diseases.Biogerontology · 2026Review
- Mapping the evolution of kainate receptor research over five decades: trends, hotspots, and emerging frontiers.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stir-fried atractylodis macrocephalae rhizoma (AMR) with aurantii fructus (AF) (SFALCA), a classical prescription of traditional Chinese medicine (TCM), has been widely used for promoting gastrointestinal health for centuries, with multiple pharmacological properties such as anti-tumor, anti-inflammatory, anti-aging, antioxidant, and antibacterial effects. Inflammatory bowel disease (IBD) is an immune-mediated chronic gastrointestinal inflammatory disorder that causes long-term distress to patients. Despite its widespread use, the specific effects of SFALCA on intestinal barrier function and underlying mechanisms remain unclear. Furthermore, interspecies discrepancies in animal studies and the physiological constraints of existing Methods: To investigate the active components, mechanisms of SFALCA in treating IBD and assesses its safety. We designed an innovative organ-on-a-chip system to simulate the human intestinal and liver environment. By stimulating with LPS/PMA, we established an Results: The results showed that SFALCA and its extracts significantly increased transepithelial electrical resistance (TEER) and Zonula occludens-1 (ZO-1) expression, while inhibiting LPS/PMA-induced IL-6 levels and the proportion of M1 macrophages. Further analysis revealed that the main active components of SFALCA, Atractylenolide I and Naringin, exert anti-inflammatory effects by inhibiting the Interleukin-17C (IL-17C) mediated positive feedback loop. Additionally, organ-on-a-chip technology confirmed that SFALCA showed no significant toxicity to the liver. Conclusion: In conclusion, this study elucidates the active components and mechanisms of SFALCA in treating IBD and assesses its safety, providing a reliable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.